Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
作者信息
Kimura Shinya
出版信息
Rinsho Ketsueki. 2009 Jul;50(7):547-55.
PMID:19638722
Abstract
摘要
相似文献
1
Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.开发用于治疗伊马替尼耐药慢性粒细胞白血病患者的新型酪氨酸激酶抑制剂。
Rinsho Ketsueki. 2009 Jul;50(7):547-55.
2
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.博舒替尼、达沙替尼和尼罗替尼对18种伊马替尼耐药的BCR/ABL突变体的活性。
J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15.
3
New and established tyrosine kinase inhibitors for chronic myeloid leukemia.用于慢性粒细胞白血病的新型及已上市的酪氨酸激酶抑制剂。
Drugs Today (Barc). 2012 Sep;48(9):601-13. doi: 10.1358/dot.2012.48.9.1869590.
4
Kinase inhibitors in chronic myelogenous leukemia.慢性粒细胞白血病中的激酶抑制剂
Clin Adv Hematol Oncol. 2006 May;4(5):365-74.
5
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.治疗相关因素、患者相关因素和疾病相关因素与酪氨酸激酶抑制剂治疗慢性髓系白血病的不良反应的发生有关。
Pharmacotherapy. 2013 Aug;33(8):868-81. doi: 10.1002/phar.1266. Epub 2013 Apr 3.
6
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.慢性粒细胞白血病治疗中的新型药物：酪氨酸激酶抑制剂及其他。
Hematology Am Soc Hematol Educ Program. 2008:427-35. doi: 10.1182/asheducation-2008.1.427.
7
Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.慢性髓性白血病或费城染色体阳性急性淋巴细胞白血病患者移植后时期的第二代酪氨酸激酶抑制剂
Acta Haematol. 2009;122(1):6-10. doi: 10.1159/000228587. Epub 2009 Jul 15.
8
[Development of ABL tyrosine kinase inhibitors].
Rinsho Ketsueki. 2010 Aug;51(8):597-604.
9
[Novel anti-CML agents beyond imatinib].[除伊马替尼之外的新型抗慢性粒细胞白血病药物]
Rinsho Ketsueki. 2007 Jun;48(6):475-84.
10
Oral BMS-354825 rescues Gleevec-resistant CML.口服BMS-354825可挽救对格列卫耐药的慢性粒细胞白血病。
Cancer Biol Ther. 2004 Aug;3(8):700.
Zotero 插件